Cargando…

Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment

BACKGROUND: Bariatric patients showing poor "focus" during treatment more often failed to lose weight or maintain reduced weight. Evaluation of these patients identified a number having attention deficit/hyperactivity disorder (ADHD), evidently a potent factor limiting successful weight co...

Descripción completa

Detalles Bibliográficos
Autor principal: Altfas, Jules R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130024/
https://www.ncbi.nlm.nih.gov/pubmed/12227832
http://dx.doi.org/10.1186/1471-244X-2-9
_version_ 1782120375427006464
author Altfas, Jules R
author_facet Altfas, Jules R
author_sort Altfas, Jules R
collection PubMed
description BACKGROUND: Bariatric patients showing poor "focus" during treatment more often failed to lose weight or maintain reduced weight. Evaluation of these patients identified a number having attention deficit/hyperactivity disorder (ADHD), evidently a potent factor limiting successful weight control. After searches found no published reports describing comorbid ADHD and obesity, this report was conceived to begin exploring the prevalence and characteristics of these patients. METHOD: Clinical records of 215 patients receiving obesity treatment during 2000 were reviewed. Data collected and analyzed included age, sex, beginning and ending body mass index (BMI), number of clinic visits, months of treatment, and diagnostic category (ADHD, some ADHD symptoms, non-ADHD). DSM-IV criteria were used, except age of onset was modified to <= 12 years. RESULTS: Whole sample ADHD prevalence was 27.4% (CI:21.1,32.9), but 42.6% (CI: 36.3% to 48.9%) for BMI >= 40. Mean weight loss among obese patients with ADHD (OB+ADHD) was 2.6 BMI (kg/m(2)) vs. 4.0 for non-ADHD (NAD) (p < 0.002). For BMI >= 40, OB+ADHD had BMI loss 2.9 vs. 7.0 (NAD) (p < 0.004). OB+ADHD had more clinic visits, with a trend toward longer treatment duration. CONCLUSIONS: ADHD was highly prevalent among obese patients and highest in those with extreme obesity. Comorbid obesity and ADHD symptoms rendered treatment less successful compared to NAD counterparts. Reasons for the comorbidity are unknown, but may involve brain dopamine or insulin receptor activity. If replicated in further studies, these findings have important implications for treatment of severe and extreme obesity.
format Text
id pubmed-130024
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1300242002-10-24 Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment Altfas, Jules R BMC Psychiatry Research Article BACKGROUND: Bariatric patients showing poor "focus" during treatment more often failed to lose weight or maintain reduced weight. Evaluation of these patients identified a number having attention deficit/hyperactivity disorder (ADHD), evidently a potent factor limiting successful weight control. After searches found no published reports describing comorbid ADHD and obesity, this report was conceived to begin exploring the prevalence and characteristics of these patients. METHOD: Clinical records of 215 patients receiving obesity treatment during 2000 were reviewed. Data collected and analyzed included age, sex, beginning and ending body mass index (BMI), number of clinic visits, months of treatment, and diagnostic category (ADHD, some ADHD symptoms, non-ADHD). DSM-IV criteria were used, except age of onset was modified to <= 12 years. RESULTS: Whole sample ADHD prevalence was 27.4% (CI:21.1,32.9), but 42.6% (CI: 36.3% to 48.9%) for BMI >= 40. Mean weight loss among obese patients with ADHD (OB+ADHD) was 2.6 BMI (kg/m(2)) vs. 4.0 for non-ADHD (NAD) (p < 0.002). For BMI >= 40, OB+ADHD had BMI loss 2.9 vs. 7.0 (NAD) (p < 0.004). OB+ADHD had more clinic visits, with a trend toward longer treatment duration. CONCLUSIONS: ADHD was highly prevalent among obese patients and highest in those with extreme obesity. Comorbid obesity and ADHD symptoms rendered treatment less successful compared to NAD counterparts. Reasons for the comorbidity are unknown, but may involve brain dopamine or insulin receptor activity. If replicated in further studies, these findings have important implications for treatment of severe and extreme obesity. BioMed Central 2002-09-13 /pmc/articles/PMC130024/ /pubmed/12227832 http://dx.doi.org/10.1186/1471-244X-2-9 Text en Copyright © 2002 Altfas; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Altfas, Jules R
Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title_full Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title_fullStr Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title_full_unstemmed Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title_short Prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
title_sort prevalence of attention deficit/hyperactivity disorder among adults in obesity treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130024/
https://www.ncbi.nlm.nih.gov/pubmed/12227832
http://dx.doi.org/10.1186/1471-244X-2-9
work_keys_str_mv AT altfasjulesr prevalenceofattentiondeficithyperactivitydisorderamongadultsinobesitytreatment